Black Diamond's May 2026 silevertinib update showed steady NSCLC response rates, CNS activity and dose progress, but durability data remain early.

Merck says its vaccine against bronchitis in chickens has been approved by the Chinese agriculture ministry for use in the ...

By Nancy Lapid May 6 (Reuters) - An experimental drug from Revolution Medicines that nearly doubled survival time for patients with advanced pancreas cancer in clinical trials comes with a high rate ...

Researchers evaluated whether daraxonrasib, an oral RAS(ON) multiselective inhibitor that targets guanosine triphosphate-bound mutant and wild-type RAS, would be safe and effective in patients with ...

As rates of cancer rise in young people,, Ph.D., wants those living with the disease to know that they don’t have to give up on their dreams. Burke herself just ac ...

Black Diamond Therapeutics (NASDAQ:BDTX) reported updated Phase 2 data for silevertinib in treatment-naive non-small cell ...

May 2026Camizestrant in combination with a CDK4/6 inhibitor recommended for approval in the EU by CHMP for 1st-line advanced ER-positive breast cancer Recommendation based on SERENA-6 Phase III trial ...

Mutation dynamics and fitness effects lie at the heart of evolutionary change. Every generation, genomes accrue spontaneous alterations ranging from single-nucleotide substitutions to larger ...

RBC Capital Markets Global Healthcare Conference 2026 May 19, 2026 10:30 AM EDTCompany ParticipantsSteven Stein - Executive ...

EU Committee recommends approval of AstraZeneca’s camizestrant for 1st-line advanced ER-positive breast cancer: Cambridge, UK Monday, May 25, 2026, 09:00 Hrs [IST] AstraZenecas ...